Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer

Table 2 Response criteria as defined by response evaluation criteria in solid tumors, world health organization, and the research and treatment of cancer

	RECIST	WHO	EORTC
Complete remission	Disappearance of all disease	Disappearance of all disease	Complete resolution of FDG uptake within the tumor volume
Partial remission	Decrease ≥ 30% in the sum of the greatest dimension of all measurable disease	Decrease ≥ 50% in the sum of the cross products	A reduction of a minimum of 15%-25% in tumor FDG SUV after one cycle of chemotherapy, and greater than 25% after more than one treatment cycle
Stable disease	Decrease < 30% and increase < 20% in the sum of the greatest tumor dimensions	Decrease < 50% and increase < 20% in the sum of the cross products	Increase of less than 25% or a decrease of less than 15% in tumor FDG SUV and no visible increase in extent (20% in the longest dimension)
Progressive disease	Increase ≥ 20% in the sum of the greatest tumor dimensions	Increase ≥ 50% in the sum of the cross products	Increase in FDG tumor SUV of greater than 25% within the tumor region, or increase of extend of FDG uptake (20% in the longest direction) or appearance of new lesions

RECIST: Response evaluation criteria in solid tumors; WHO: World health organization; EORTC: Research and treatment of cancer; FDG: F-2-fluoro-2-deoxyglucose; SUV: Standardised uptake value.